Lupu R - Search Results

1

Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells.

Grunt TW, Saceda M, Martin MB, Lupu R, Dittrich E, Krupitza G, Harant H, Huber H, Dittrich C. Grunt TW, et al. Among authors: lupu r. Int J Cancer. 1995 Nov 15;63(4):560-7. doi: 10.1002/ijc.2910630417. Int J Cancer. 1995. PMID: 7591267

2

Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells.

Tang CK, Perez C, Grunt T, Waibel C, Cho C, Lupu R. Tang CK, et al. Among authors: lupu r. Cancer Res. 1996 Jul 15;56(14):3350-8. Cancer Res. 1996. PMID: 8764133

3

Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines.

Saceda M, Grunt TW, Colomer R, Lippman ME, Lupu R, Martin MB. Saceda M, et al. Among authors: lupu r. Endocrinology. 1996 Oct;137(10):4322-30. doi: 10.1210/endo.137.10.8828492. Endocrinology. 1996. PMID: 8828492

4

Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells.

Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, Zielinski CC, Lupu R. Grunt TW, et al. Among authors: lupu r. Biochem Biophys Res Commun. 2009 Jul 31;385(3):454-9. doi: 10.1016/j.bbrc.2009.05.085. Epub 2009 May 23. Biochem Biophys Res Commun. 2009. PMID: 19467222

5

Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells.

Puricelli L, Proietti CJ, Labriola L, Salatino M, Balañá ME, Aguirre Ghiso J, Lupu R, Pignataro OP, Charreau EH, Bal de Kier Joffé E, Elizalde PV. Puricelli L, et al. Among authors: lupu r. Int J Cancer. 2002 Aug 20;100(6):642-53. doi: 10.1002/ijc.10533. Int J Cancer. 2002. PMID: 12209601 Free article.

6

The significance of heregulin in breast cancer tumor progression and drug resistance.

Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Rosenberg K, Yang D, Tang C. Lupu R, et al. Breast Cancer Res Treat. 1996;38(1):57-66. doi: 10.1007/BF01803784. Breast Cancer Res Treat. 1996. PMID: 8825123 Review.

7

Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines.

Hartmann F, Horak EM, Cho C, Lupu R, Bolen JB, Stetler-Stevenson MA, Pfreundschuh M, Waldmann TA, Horak ID. Hartmann F, et al. Among authors: lupu r. Int J Cancer. 1997 Jan 17;70(2):221-9. doi: 10.1002/(sici)1097-0215(19970117)70:2<221::aid-ijc14>3.0.co;2-l. Int J Cancer. 1997. PMID: 9009164 Free article.

8

Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.

Xu F, Lupu R, Rodriguez GC, Whitaker RS, Boente MP, Berchuck A, Yu Y, DeSombre KA, Boyer CM, Bast RC Jr. Xu F, et al. Among authors: lupu r. Int J Cancer. 1993 Feb 1;53(3):401-8. doi: 10.1002/ijc.2910530310. Int J Cancer. 1993. PMID: 7679090

9

Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance.

Lupu R, Cardillo M, Harris L, Hijazi M, Rosenberg K. Lupu R, et al. Semin Cancer Biol. 1995 Jun;6(3):135-45. doi: 10.1006/scbi.1995.0016. Semin Cancer Biol. 1995. PMID: 7495981 Free article. Review.

10

Expression of estrogen receptor beta messenger RNA variant in breast cancer.

Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lupu R. Vladusic EA, et al. Among authors: lupu r. Cancer Res. 1998 Jan 15;58(2):210-4. Cancer Res. 1998. PMID: 9443393

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

165 results

Search Page